MYND VOTE 7/9 on Emmaus Life Sciences reverse merger!
found this article was posted from 2017 entitled, "Mystery biotech Emmaus grabs groundbreaking FDA panel backing for sickle cell drug — after quietly scrapping $225M deal"
it seems Emmaus scrapped the deal when it was apparent the FDA was going to approve Endari, the Sickle Cell Disease drug. probably because Emmaus mgmt knew they were worth more. so what's Emmaus worth now?
according to this Sickle Cell research article the Sickle Cell market size is $2.1B, growing to $4.5B by 2025. the article also list the key players. Emmaus is first on the list;
The key players covered in this study: Emmaus Medical Addmedica Gamida Cell GlycoMimetics Pfizer Novartis Global Blood Therapeutics Micelle BioPharma Bluebird Bio Prolong Pharmaceuticals Modus Therapeutics Sangamo Biosciences Bioverativ Imara Ironwood Pharmaceuticals
nice timing! out of curiosity, did you buy the MYND or the warrants, MYNDW? it seems the news that MYND is lowering the strike of MYNDW from $5.25 to $2.00 makes the warrants substantially more valuable than they were, with HUGE leverage should MYND really take off.